Molecular Basis of Cancer

The molecular basis of cancer is the set of genetic and epigenetic alterations that drive neoplastic behavior. Cancer arises from changes in two principal classes of genes — oncogenes, whose activation promotes growth, and tumor suppressor genes, whose loss removes growth restraints — together with alterations in genes that maintain genome integrity. These changes deregulate a finite number of signaling pathways that govern cell proliferation, survival, and differentiation.

Definition

The molecular basis of cancer comprises the heritable genetic and epigenetic alterations — chiefly activation of oncogenes, inactivation of tumor suppressor genes, and disruption of genome-maintenance genes — that deregulate the signaling pathways controlling cell growth, survival, and differentiation.

Scope

This topic covers proto-oncogenes and their activation into oncogenes, tumor suppressor genes and the conditions of their inactivation, genome-maintenance (caretaker) genes, and the core signaling pathways through which these alterations act. It also addresses cancer genome landscapes and the distinction between driver and passenger mutations. It is a mechanistic, reference-educational topic and does not provide treatment guidance.

Core questions

• How do proto-oncogenes become cancer-promoting oncogenes?
• Why does loss of tumor suppressor function typically require inactivation of both alleles?
• How do caretaker (genome-maintenance) genes contribute to cancer when defective?
• How do diverse mutations converge on a limited set of signaling pathways?

Key concepts

• Proto-oncogenes and oncogenes
• Tumor suppressor genes and the two-hit model
• Caretaker and gatekeeper genes
• Driver versus passenger mutations
• Signaling pathways (growth, survival, cell-cycle control)
• Epigenetic alterations
• Genome instability
• Cancer genome landscapes

Key theories

Oncogene and tumor suppressor paradigm

Cancer-driving alterations fall into two complementary classes: gain-of-function changes that activate oncogenes (acting dominantly) and loss-of-function changes that inactivate tumor suppressor genes (typically requiring loss of both alleles), with both converging to deregulate growth control.

Driver versus passenger mutations

Genome-wide cancer studies distinguish a relatively small number of driver mutations that confer a selective growth advantage from the many passenger mutations that accumulate without driving tumorigenesis, refining the view of which alterations cause cancer.

Mechanisms

Cancer-driving alterations act through a small number of mechanisms. Proto-oncogenes are converted to oncogenes by point mutation, amplification, or translocation, producing gain-of-function signals that sustain proliferation; because a single activated allele suffices, oncogenes act dominantly. Tumor suppressor genes restrain growth or promote death, and their inactivation generally requires loss of both alleles (the two-hit model), removing key checkpoints. Caretaker genes maintain genome integrity, and their loss raises the mutation rate, accelerating acquisition of further drivers. Genome-wide sequencing shows that the many mutations in a tumor include a limited set of drivers that converge on a finite number of signaling pathways controlling proliferation, survival, and differentiation, alongside epigenetic alterations that similarly deregulate gene expression.

Clinical relevance

Molecular characterization of oncogenes, tumor suppressors, and pathway alterations underpins molecular diagnosis, classification, and the conceptual basis for biomarker-guided and targeted approaches. As a reference topic it explains the genetic logic of cancer; it describes mechanisms and is not a basis for individual testing or therapy decisions, which depend on validated clinical workflows.

Epidemiology

The number and identity of driver alterations vary substantially across tumor types, from cancers with few drivers to highly mutated genomes. This molecular diversity, revealed by large-scale genome studies, parallels the clinical and histological heterogeneity of cancer.

History

The discovery of cellular proto-oncogenes and, in parallel, the recognition of tumor suppressor genes through Knudson's two-hit analysis established the genetic foundation of cancer in the 1970s and 1980s. Vogelstein and Kinzler's synthesis of cancer genes and their pathways, and later the cancer-genome-landscape studies enabled by high-throughput sequencing, distinguished drivers from passengers and showed that diverse mutations converge on a limited set of regulatory pathways.

Key figures

• Bert Vogelstein
• Kenneth Kinzler
• Alfred Knudson
• Douglas Hanahan
• Robert Weinberg

Seminal works

• vogelstein-2004
• vogelstein-2013
• vogelstein-1988

Frequently asked questions

What is the difference between an oncogene and a tumor suppressor gene?

An oncogene is an activated, gain-of-function gene whose product promotes cancerous growth; a single altered allele is usually enough (dominant). A tumor suppressor gene normally restrains growth, and cancer arises when its function is lost, typically requiring inactivation of both alleles.

What are driver and passenger mutations?

Driver mutations confer a selective growth advantage and contribute causally to cancer, whereas passenger mutations are incidental alterations that accumulate in a tumor without driving its development. Distinguishing them is a central aim of cancer genome analysis.